Casdin Capital BLFS Position
ActiveCasdin Capital trimmed their position in BIOLIFE SOLUTIONS INC (BLFS) in Q4 2025, holding $144.0M worth of shares across 5,957,165 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
1 other tracked fund also holds BLFS.
About BIOLIFE SOLUTIONS INC
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
Full company profile →Short Interest
9.1%
6.2 days to cover
Casdin Capital BLFS Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Decreased | 5,957,165 | -750,000 | $144.0M |
| Q3 2025 | Decreased | 6,707,165 | -1,000,000 | $171.1M |
| Q2 2025 | Decreased | 7,707,165 | -1,000,000 | $166.0M |
| Q1 2025 | Held | 8,707,165 | — | $198.9M |
| Q4 2024 | Held | 8,707,165 | — | $226.0M |
| Q3 2024 | Held | 8,707,165 | — | $218.0M |
| Q2 2024 | Held | 8,707,165 | — | $186.6M |
| Q1 2024 | Held | 8,707,165 | — | $161.5M |
| Q4 2023 | Increased | 8,707,165 | +927,165 | $141.5M |
| Q3 2023 | Increased | 7,780,000 | +58,465 | $107.4M |
| Q2 2023 | Increased | 7,721,535 | +150,000 | $170.6M |
| Q1 2023 | New | 7,571,535 | +7,571,535 | $164.7M |
Frequently Asked Questions
Does Casdin Capital own BLFS?
Yes. As of Q4 2025, Casdin Capital holds 5,957,165 shares of BIOLIFE SOLUTIONS INC (BLFS) valued at $144.0M. This data comes from their SEC 13F filing.
How many hedge funds own BLFS?
2 specialist biotech hedge funds currently hold BLFS, including Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Casdin Capital first buy BLFS?
Casdin Capital's position in BLFS was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Casdin Capital's BLFS position increasing or decreasing?
Casdin Capital trimmed their BLFS position in the most recent quarter, reducing by 750,000 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
BLFSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Casdin CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →